29 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp06724 | L14 | ALWKSILKNAGKALNEINQIVQ | Dermaseptin-SS1- Analog | Membrane Permeabilization | MTT assay | H-460 | Lung Cancer | IC50 = 20.1 µM |
| dbacp06726 | 14V | ALWKSILKNAGKAVLNEINQIVQ | Dermaseptin-SS1- Analog | Membrane Permeabilization | MTT assay | H-460 | Lung Cancer | IC50 = 4.1 µM |
| dbacp06728 | 14G | ALWKSILKNAGKAGLNEINQIVQ | Dermaseptin-SS1- Analog | Membrane Permeabilization | MTT assay | H-460 | Lung Cancer | IC50 = 31.7 µM |
| dbacp06730 | L2V | ALWKSILKNVGKVLNEINQIVQ | Dermaseptin-SS1- Analog | Membrane Permeabilization | MTT assay | H-460 | Lung Cancer | IC50 = 0.6 µM |
| dbacp06732 | 14V5K | ALWKKILKNAGKAVLNEINQIVQ | Dermaseptin-SS1- Analog | Membrane Permeabilization | MTT assay | H-460 | Lung Cancer | IC50 = 6.1 µM |
| dbacp06734 | 14VL23 | ALWKSILKNAGKAVLNEINQIV | Dermaseptin-SS1- Analog | Membrane Permeabilization | MTT assay | H-460 | Lung Cancer | IC50 = 16.4 µM |
| dbacp06801 | A11 | EYVQTVKSSKG | Annexin A1 | Targeting PD-L2 | Biotin Pull Down assay | H-460 | Lung Cancer | Not Available |
| dbacp06903 | CIGB-300 | GRKKRRQRRRPPQ-X-CWMSPRHLGTC | Synthetic | Cell Penetration | Crystal Violet assay | NCI-H-460 | Lung Cancer | IC50 = 30 ± 5.3 µM |
| dbacp06914 | AC-P19M | FAKKLAKLKKKLAKLAKKR | Synthetic analogue of AC-P19 | Inhibition of cell signalling | WST-8 assay | H-460 | Lung Cancer | IC50 = 6.29 µM |
| dbacp06916 | AC-P19 | FAKKLAKLKKKLAKLALAL | Synthetic | Inhibition of cell signalling | WST-8 assay | H-460 | Lung Cancer | IC50 = 49.08 µM |
| dbacp06942 | HTDT-6-2-3-2 | GPLGAGP | Enteromorpha prolifera | Apoptosis inducing | CCK-8 assay | NCI-H-460 | Lung Cancer | IC50 = 0.3686 ± 0.0935 mg/mL |
| dbacp07102 | rScyreprocin | MKEDSNILDKTAKMTKQNKALLFTAGGAAAFMAGYYYYHCNYRNPAPKKSGSTTSQDKTDAQAVQSIPSPSGNKGKESKDPKVKHHHHHH | Recombinant product of Scyreprocin | Membrane disruption triggers ROS-mediated apoptosis | MTS assay | H-460 | Lung Cancer | IC50 = 6.27 µM |
| dbacp07244 | CIGB-552 | HARIKpTFRRlKWKYKGKFW | Synthetic | NF-κB inhibition enhances cisplatin synergy | Sulforhodamine B assay | NCI-H-460 | Lung Cancer | IC50 = 287.9 μM |
| dbacp07338 | Temporin-HLa | FFPLIFGALSSILPKIL | Hylarana latouchii | Membrane disruption | MTT assay | H-460 | Lung Cancer | IC50 = 1.64 ± 0.41 μM |
| dbacp07467 | Tachyplesin | KWCFRVCYRGICYIRRCR | Horseshoe crab | Fas activation drives apoptosis/necroptosis | MTT assay | H-460 | Lung Cancer | IC50 = 25 µg/ml |
| dbacp07644 | Colicin N | HGDNNSKPKPGGNSGNRGNNGDGASAKVGEITITPDNSKPGRYISSNPEYSLLAKLIDAESIKGTEVYTFHTRKGQYVKVTVPDSNIDKMRVDYVNWKGPKYNNKLVKRFVSQFLLFRKEEKEKNEKEALLKASELVSGMGDKLGEYLGVKYKNVAKEVANDIKNFHGRNIRSYNEAMASLNKVLANPKMKVNKSDKDAIVNAWKQVNAKDMANKIGNLGKAFKVADLAIKVEKIREKSIEGYNTGNWGPLLLEVESWIIGGVVAGVAISLFGAVLSFLPISGLAVTALGVIGIMTISYLSSFIDANRVSNINNIISSVIR | Apoptosis via integrin-Akt suppression | MTT assay | H-460 | Lung Cancer | Dose dependent % cell viability resuctuction at 1-15 µM | |
| dbacp07867 | R-Lycosin I derivative 8a | RGWFRAMRSIARFIARERLRGHL | Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I | GLUT1-mediated uptake enhances cytotoxicity | CCK-8 assay | H-460 | Lung Cancer | IC50 = 8.5 ± 0.4 µM |
| dbacp07873 | R-Lycosin I derivative 8b | RGWFRAMRSIARFIARERLRGHL | Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I | GLUT1-mediated uptake enhances cytotoxicity | CCK-8 assay | H-460 | Lung Cancer | IC50 = 4.9 ± 0.9 µM |
| dbacp07877 | Fi-Histin1-21 | SRSSRAGLQFPVGRIHRLLRK | Fenneropenaeus indicus | Membrane disruption and DNA binding | XTT assay | NCI-H-460 | Lung Cancer | IC50 = 22.670 ± 13.939 μM |
| dbacp07995 | [G10a]SHa | FLSGIVGMLaKLF | Synthetic analogue of Temporin-1SHa | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | NCI-H-460 | Lung Cancer | IC50 =24.3 ± 0.8 µM |
| dbacp07998 | [G10a]SHa-BCTP | FLSGIVGMLaKLFLFKQYAELW | Synthetic analogue of Temporin-1SHa | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | NCI-H-460 | Lung Cancer | IC50 >100 µM |
| dbacp08001 | [G4a]SHa | FLSaIVGMLGKLF | Synthetic analogue of Temporin-1SHa | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | NCI-H-460 | Lung Cancer | IC50 >100 µM |
| dbacp08004 | [G7a]SHa | FLSGIVaMLGKLF | Synthetic analogue of Temporin-1SHa | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | NCI-H-460 | Lung Cancer | IC50 >100 µM |
| dbacp08007 | [G4,7a]SHa | FLSaIVaMLGKLF | Synthetic analogue of Temporin-1SHa | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | NCI-H-460 | Lung Cancer | IC50 = 37.3 ± 3.5 µM |
| dbacp08010 | [G4,7,10a]SHa | FLSaIVaMLaKLF | Synthetic analogue of Temporin-1SHa | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | NCI-H-460 | Lung Cancer | IC50 >100 µM |
| dbacp08013 | [G7,10a]SHa | FLSGIVaMLaKLF | Synthetic analogue of Temporin-1SHa | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | NCI-H-460 | Lung Cancer | IC50 >100 µM |
| dbacp08016 | Ec-LDP-hBD1 | MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH | Synthetic | EGFR-targeted defensin induces mitochondrial apoptosis | CCK-8 assay | H-460 | Lung Cancer | IC50 = 5.19 μM |
| dbacp08039 | Silk Fibroin peptide | Not Available | Silkworm Cocoons | SFP induces S-phase cell-cycle arrest | MTT assay | H-460 | Lung Cancer | IC50 = 9.083 ± 1.22 mg/ml |
| dbacp08360 | Seq ID No. 26 from patent ID US202000079827A1 | RRWVRRVRRVWRRVVRVVRRWVRR | Synthetic | Not Available | Tetrazolium-based assay | H-460 | Lung Cancer | Cell viability < 50% at 20 μM |